Cibus Q2 Loss Narrows to $22.1M; Cash Runway Extended to Early Q1 2027
CBUS sits 54% above its 52-week low of $1.09.
Summary
Q2 2026 results showed a narrower net loss and extended cash runway into early Q1 2027, alongside expanded Rice trait partnerships and updated launch timelines.
Key Events · Earnings and Guidance · CBUS
-
Q2 Net Loss Narrows
Net loss was $22.1 million for Q2 2026, down from $26.6 million in Q2 2025, driven by cost reduction initiatives.
-
Cash Runway Extended
Cash of $20.4 million as of June 30, 2026 is expected to fund operations into early Q1 2027, reflecting reduced cash usage.
-
Interoc Partnership Expanded
LOI with Interoc expanded from two to five Rice traits, supporting potential commercialization in Latin America.
-
Launch Targets Updated
Initial commercial launch targets set for 2028 in LATAM (Fedearroz and Interoc) and 2029 in the US (paired with Albaugh's herbicide registration).
Analysis · CBUS · Industrial Applications And Services
A narrower Q2 net loss of $22.1 million, down from $26.6 million a year ago, reflects the impact of cost reductions. With $20.4 million in cash, the company now expects to fund operations into early Q1 2027, extending its runway beyond prior guidance. The Interoc partnership was expanded from two to five Rice traits, and launch targets were updated to 2028 in LATAM and 2029 in the US. While the loss remains significant, the improved cash position and commercial progress are positive for a company with a going concern warning.
At the time of this filing, CBUS was trading at $1.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $145M. The 52-week trading range was $1.09 to $4.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.